Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

GLUE vs ARVN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ARVN Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–5 Matrix Metrics)

ARVN Overall Winner 6-Pillar Tally: GLUE 2 – 3 ARVN (1 Tie) Matrix Metrics: GLUE 5 – 5 ARVN

As of Nov 16, 2026, Arvinas, Inc (ARVN) is the stronger overall head-to-head candidate over Monte Rosa Therapeutics, Inc. (GLUE) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). GLUE carries a Unified Composite Score of 44.2/100 (HOLD) at $9.18 (10.0x Forward P/E, -214.5% operating margin), whereas ARVN carries 52.9/100 (HOLD) at $6.74 (17.9x Forward P/E, -10.1% operating margin).

  • Growth vs. Quality Trade-Off: ARVN earns the overall head-to-head edge with a stronger Unified Composite Score (52.9/100 HOLD vs. GLUE 44.2/100 HOLD) and 1.40β · 66% Vol risk profile, whereas GLUE leads top-line expansion (+325.8% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: GLUE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile ARVN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GLUE vs ARVN
GLUE NASDAQ
Monte Rosa Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.18
-2.03% 1D
Market Cap $795.5M
TTM Revenue $70M
Forward P/E 10.0x
Beta / 30D Vol 0.95β · 53% Vol
Unified Composite Score
44.2 / 100 HOLD
Tech 32.0 Fund 51.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.2%), weak momentum, RSI 31
RSI-14: 31.3 · SMA20: $10.50 · SMA50: $11.21
ARVN NASDAQ Head-to-Head Winner
Arvinas, Inc
Pharmaceutical Preparations
$6.74
-1.17% 1D
Market Cap $449.9M
TTM Revenue $275M
Forward P/E 17.9x
Beta / 30D Vol 1.40β · 66% Vol
Unified Composite Score
52.9 / 100 HOLD
Tech 54.0 Fund 59.0 Flow 71.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.6%), weak momentum, RSI 42
RSI-14: 41.7 · SMA20: $7.22 · SMA50: $7.57

6-Pillar Scorecard Institutional Category Breakdown (GLUE 2 – 3 ARVN)

Columns: Metric · GLUE · ARVN
1. Valuation Multiples GLUE
Forward P/E 10.0x 17.9x
Trailing P/E 10.0x 17.9x
PEG Ratio N/M N/M
EV / Revenue 11.2x 1.3x
2. Growth & Scale GLUE
Revenue Growth (YoY) +325.8% -98.8%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $70M $275M
Market Cap $795.5M $449.9M
3. Profitability & Quality ARVN
Gross Margin -92.2% 96.7%
Operating Margin -214.5% -10.1%
Net Profit Margin -186.2% -3.5%
Return on Equity (ROE) -35.3% -1.8%
4. Balance Sheet & Cash Flow ARVN
Cash Generation (TTM) -$174M -$160M
Cash Flow Margin N/A -58.0%
Net Cash / Leverage $8.9M Net Cash $81M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ARVN
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 100.8% (16th %ile) 108.7% (25th %ile)
Put/Call OI Skew 6.27x (Put-Skewed) 0.01x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GLUE (5) vs ARVN (5)
Institutional Metric GLUE ARVN Criterion Row Edge
Market Capitalization
Scale
$795.5M $449.9M Larger Scale GLUE
Trailing P/E Ratio
Valuation
10.0x 17.9x Lower Multiple GLUE
Forward P/E Ratio
Valuation
10.0x 17.9x Lower Multiple GLUE
Revenue Growth (YoY)
Growth
+325.8% -98.8% Higher Growth GLUE
Operating Margin (TTM)
Profitability
-214.5% -10.1% Higher Margin ARVN
Net Profit Margin
Profitability
-186.2% -3.5% Higher Margin ARVN
Return on Equity (ROE)
Capital Efficiency
-35.3% -1.8% Higher ROE ARVN
52-Week Range Position
Momentum
1% ($9–$26) 5% ($6–$15) Stronger Trend ARVN
Beta / 30D Volatility
Risk Regime
0.95β · 53% Vol 1.40β · 66% Vol Lower Realized Risk GLUE
Unified Institutional Score
Composite Signal
44.2 / 100 (HOLD) 52.9 / 100 (HOLD) Higher Composite ARVN
Trailing 12M Revenue (USD)
Operating Scale
$70M $275M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-92.2% 96.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 11.2x EV/Rev N/M PEG · 1.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$174M ($8.9M Net Cash) -$160M ($81M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ARVN +2.45 pp
GLUE: -5.75% · ARVN: -3.3%
3M Horizon ARVN +11.71 pp
GLUE: -38.92% · ARVN: -27.21%
6M Horizon ARVN +25.8 pp
GLUE: -49.03% · ARVN: -23.23%
1Y Horizon ARVN +2.49 pp
GLUE: -35.89% · ARVN: -33.4%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period GLUE Revenue ARVN Revenue GLUE Op. Margin ARVN Op. Margin Margin Leader
FY2018 N/A $10M N/A -306.3% ARVN
FY2019 N/A $20M N/A -281.4% ARVN
FY2020 N/A $20M N/A -554.1% ARVN
FY2021 N/A $50M N/A -403.4% ARVN
FY2022 N/A $130M N/A -200.3% ARVN
FY2023 N/A $80M N/A -511.5% ARVN
FY2024 $80M $260M -107.3% -95.0% ARVN
FY2025 $120M $260M -43.8% -45.1% GLUE

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GLUE BREAKDOWN
85d in phase · OBV DISTRIBUTION
Current IV 100.8%
IV Percentile 16th %ile
Put/Call OI Skew 6.27x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact GLUE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ARVN BREAKDOWN
62d in phase · OBV DISTRIBUTION
Current IV 108.7%
IV Percentile 25th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ARVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GLUE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $795.5M market capitalization and -214.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ARVN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $449.9M market capitalization and -10.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ GLUE vs ARVN Key Questions & Quantitative Answers

As of Nov 16, 2026, Arvinas, Inc (ARVN) is the stronger overall head-to-head candidate over Monte Rosa Therapeutics, Inc. (GLUE) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). GLUE carries a Unified Composite Score of 44.2/100 (HOLD) at $9.18 (10.0x Forward P/E, -214.5% operating margin), whereas ARVN carries 52.9/100 (HOLD) at $6.74 (17.9x Forward P/E, -10.1% operating margin). Growth vs. Quality Trade-Off: ARVN earns the overall head-to-head edge with a stronger Unified Composite Score (52.9/100 HOLD vs. GLUE 44.2/100 HOLD) and 1.40β · 66% Vol risk profile, whereas GLUE leads top-line expansion (+325.8% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: GLUE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile ARVN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GLUE leads the Growth & Scale pillar: GLUE posts +325.8% YoY revenue growth and +0.0% YoY earnings growth on $70M TTM revenue (-92.2% gross margin, -214.5% operating margin), compared with ARVN at -98.8% YoY revenue growth and +0.0% YoY earnings growth on $275M TTM revenue (96.7% gross margin, -10.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), GLUE cumulative revenue shifted +50.0% while ARVN shifted +2500.0%. In operating R&D and SG&A reinvestment, GLUE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ARVN.

GLUE screens cheaper on headline valuation multiples. GLUE trades at 10.0x Forward P/E, 10.0x Trailing P/E, N/M PEG, and 11.2x EV/Revenue (unreported FCF margin), whereas ARVN trades at 17.9x Forward P/E, 17.9x Trailing P/E, N/M PEG, and 1.3x EV/Revenue (-58.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GLUE (-35.3% ROE) versus ARVN (-1.8% ROE) capital efficiency.

In options market volatility and institutional positioning, GLUE carries 100.8% implied volatility (16th %ile, Compressed (<25th %ile)), a 6.27x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.95β · 53% Vol realized risk). By comparison, ARVN carries 108.7% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.40β · 66% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.